With earnings season in full swing, biotechnology stocks were volatile today. If approved, avacincaptad pegol would be the first commercial rival to Apellis' FDA-approved GA medicine, Syfovre. Apellis ...

Investors in TG Therapeutics, Inc. TGTX need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 15, 2026 $15.00 Call had some of the highest ...

In trading on Monday, shares of TG Therapeutics Inc (Symbol: TGTX) crossed above their 200 day moving average of $34.34, changing hands as high as $35.07 per share. TG Therapeutics Inc shares are ...

Biotech stocks were fairly volatile today, thanks to another buyout and a spate of earnings reports. If approved, avacincaptad pegol would be the first commercial rival to Apellis' FDA-approved GA ...